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ABSTRACT  
DNA samples from formalin-fixed paraffin-embedded tissues are highly degraded with variable 
quality, and this imposes a big challenge for targeted sequencing due to false positives, largely 
caused by PCR errors and cytosine deamination.  To eliminate false positives, a common practice is 
to validate the detected variants by Sanger sequencing or perform targeted sequencing in duplicate.  
Technically, PCR errors could be removed by molecular barcoding of template DNA prior to 
amplification as in the HaloPlexHS  design.  Nonetheless, it is uncertain to what extent variants 
detected using this approach should be further validated.  Here, we addressed this question by 
correlating variant reproducibility with DNA quality using  HaloPlexHS  target enrichment and 
Illumina HiSeq4000, together with an in-house validated variant calling algorithm.  The overall 
sequencing coverage, as shown by analyses of 70 genes in 266 cases of large B-cell lymphoma, was 
excellent (98%) in DNA samples amenable for PCR of ≥400bp, but suboptimal (92%) and poor (80%) 
in those amenable for PCR of 300bp and 200bp respectively.  By mutation analysis in duplicate in 93 
cases, we demonstrated that 20 alternative allele depth (AAD) was an optimal cut-off value for 
separating reproducible from non-reproducible variants in DNA samples amenable for PCR of 
≥300bp , with 97% sensitivity and 100% specificity.  By cross validation with a previously established 
targeted sequencing protocol by Fluidigm-PCR and Illumina MiSeq, the HaloPlexHS protocol was 
shown to be highly sensitive and specific in mutation screening.  To conclude, we proposed a 
stratified approach for mutation screening by HaloplexHS and Illumina HiSeq4000 according to DNA 
quality.  DNA samples with good quality (≥400bp) are amenable for mutation analysis with a single 
replicate, with only variants at 15-20 AAD requiring for further validation, while those with 
suboptimal quality (300bp) are better analysed in duplicate with reproducible variants at >15 AAD 
regarded as true genetic changes.  
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INTRODUCTION  
Next generation sequencing (NGS) has made an unprecedented contribution to discoveries in the 
biomedical research field.  One of its many applications is targeted sequencing to screen mutations 
in a panel of interesting genes.  In view of the rapid discovery in cancer research and huge impact 
from mega genome sequencing initiatives such as the 100k genome project, it is imperative to 
establish highly sensitive, specific and also robust targeted sequencing protocol that is amenable to 
degraded DNA from formalin fixed paraffin embedded (FFPE) tissues/cells, allowing translational 
research as well as routine clinical application.  There are several target enrichment methods 
available, based on hybridisation capture (Agilent SureSelect or NimbleGen SeqCap products), PCR 
(Fluidigm Access Array PCR, RainDance technology) or a combination of both hybridisation capture 
and PCR (HaloPlexHS).  The enriched target sequence library can then be sequenced by an Illumina 
or Ion Torrent platform.  Among these different approaches, PCR-based targeted enrichment is 
commonly used due to its easy application to minute amounts of template DNA.   
There are many issues associated with targeted sequencing, particularly when using DNA samples 
from FFPE tissues.  One major issue is the uncertainty whether the variants detected are true 
genetic changes or false positives due to PCR/sequence errors, poor DNA quality and deamination 
of cytosine.  Treatment of FFPE tissue DNA with uracil glycosylase can significantly reduce false 
positives resulting from deamination of cytosine, but this has little or no effect for deamination-
induced change at 5-methyl cytosine and CpG dinucleotides.1-3  A more common practice is to 
further verify the variants detected by an independent method such as conventional Sanger 
sequencing or an alternative targeted sequencing protocol.4   Other major issues for targeted 
sequencing are suboptimal performance of variant calling algorithms particularly for indels, and a 
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lack of an experimentally established cut-off value, for example variant allele depth and frequency, 
for highly sensitive and specific detection of somatic mutations.5  
In a recent study, we have established a targeted sequencing protocol by Fluidigm Access Array PCR 
and Illumina MiSeq sequencing together with an in house validated variant calling pipeline that was 
optimised against a large number of various known mutations.6  False positives were eliminated by 
performing the targeted sequencing and data analyses in duplicate with only the variants, which 
appeared in both replicates and above the experimentally defined cut-off value of alternative allele 
frequency (AAF), being regarded as true genetic changes.6  Detailed analyses of false positives 
revealed their distinct nature and origins between high molecular weight DNA from fresh frozen 
tissues and degraded DNA from FFPE tissues.  For high molecular weight DNA, the majority of false 
positives are derived from PCR/sequencing errors, while for FFPE tissue DNA, the false positives are 
from both PCR/sequencing errors and cytosine deamination, which is caused by tissue formalin 
fixation and storage.2,6-9    
The more recent HaloPlexHS  target enrichment design incorporates a molecular barcode in 
hybridisation probes, and this allows removal of PCR errors during sequence data analysis.  Apart 
from this, the HaloPlexHS  target enrichment also offers several other advantages including easy 
probe design, high flexibility in the number of genes to be investigated, and a streamlined 
experimental protocol.  Nonetheless, it remains to be investigated whether mutation analysis can 
be reliably performed in a single replicate with DNA samples from FFPE tissues by the HaloPlexHS  
target enrichment protocol.  In the present study, we have optimised a protocol for high 
throughput mutation screening by HaloPlexHS  target enrichment and Illumina sequencing, and 
established a practical strategy for reliable mutation detection using DNA samples from FFPE 
tissues.   The strategy allowed stratification of DNA samples into different protocols of mutation 
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analyses according to their quality, with good quality DNA investigated in a single replicate, while 
sub-optimal quality DNA was analysed in duplicate.        
 
MATERIALS AND METHODS 
Tumour materials and DNA extraction: 
FFPE lymphoma specimens were retrieved from 266 cases of diffuse large B-cell lymphoma (DLBCL) 
enrolled to the REMoDL-B and MaPLe trials.  Local ethical guidelines were followed for the use of 
these tissue materials for research with the approval of the ethics committees of the involved 
institutions. 
Haematoxylin and eosin slides were reviewed and tumour rich areas (>40%) in each specimen were 
isolated by crude microdissection for DNA extraction.  DNA was extracted using the QIAamp DNA 
Micro Kit (QIAGEN, Crawley, UK) and quantified using a Qubit® Fluorometer (Life Technologies, UK).  
Assessment of DNA quality by conventional PCR.    
This was performed by PCR of variably sized genomic fragments using 2 ng template DNA in a 10 μl 
reaction mixture for 40 cycles under a standardised protocol as described previously.6 
Targeted sequencing by Fluidigm multiplex PCR and Illumina MiSeq sequencing  
This was used to investigate mutations in 22 genes in 60 cases of DLBCL as described previously.6  
Each DNA sample was simultaneously investigated in duplicate.  Briefly, 50 ng genomic DNA was 
used for preamplification and Fluidigm Access Array PCR, followed by barcoding and Illumina MiSeq 
sequencing.   Variants were identified using an in-house developed and validated variant caller 
python program.6  After filtering baseline sequence errors and germline changes through SNP 
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database search, novel variants seen in both replicates of the same sample were recorded and 
those above 10% AAF (alternative allele frequency) were regarded as true changes as defined 
previously.6 
Gene panel and target enrichment by HaloPlexHS   
A total of 70 genes (~205kb sequence) that are recurrently mutated in aggressive B-cell lymphomas 
were included in the HaloPlexHS  target enrichment design, and they included the 22 genes that 
were investigated by Fluidigm multiplex PCR and Illumina MiSeq sequencing as outlined above.6  
The HaloPlexHS target enrichment design incorporates molecular barcodes in the hybridisation 
probes, thus allowing the removal of PCR errors during sequence data analysis (Agilent 
Technologies).   HaloPlexHS target enrichment was performed essentially according to the 
manufacturer’s instructions for FFPE tissue samples.  Briefly, 100ng of genomic DNA was digested 
with restriction enzymes, and hybridized to the above customised HaloPlexHS  probe library.  The 
probe-target DNA hybrids were ligated and circularized with HS DNA ligase, then purified with 
streptavidin beads and finally amplified by PCR. 
Library purification and Illumina Sequencing 
The above amplified target library was purified twice using AMPure XP beads (Beckman Coulter, 
Pasadena, CA) to remove fragments below the expected target size.   The purified target library 
from each sample was then validated and quantified using the 4200 TapeStation (Agilent 
Technologies), and pooled with appropriate adjustment according to their concentration.   The 
pooled libraries were then sequenced on one of the following Illumina platforms:  MiSeq (2x250bp 
end sequencing protocol), HiSeq2500 (Rapid Run Mode 2x150bp end sequencing protocol), or 
HiSeq4000 (2x150bp end sequencing protocol). 
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Variants calling and data analysis 
Demultiplexing and conversion from bcl to fastq were performed using bcl2fastq v2.19, followed by 
read trimming and adaptor sequence removal with SurecallTrimmer from the Agilent Genomics 
NextGen Toolkit v4.0.1 (AGeNT). The reads were aligned to hg38 using bwa mem v0.7.17 and 
deduplication was carried out using the AGeNT LocatIt tool.  The resultant sam files were converted 
to bam with samtools v1.3.1, which was also used for sorting and indexing of bam files.10 
For SNV detection, bam files were processed using a pipeline based on GATK v3.6 best practices 
including indelrealigned and recalibration steps.  The calling variant was run using 
UnifiedGenotyper with 10000 to prevent downsampling.11  As GATK was unable to call SNVs at <8% 
AAF reliably, MuTect2 was additionally employed for detection of hotspot mutations at low AAF 
values.  Indel detection was separately carried out on the recalibrated bam files using Pindel 
v0.2.5,12 which allowed detection of indels as low as 2% AAF. 
Variant call files were concatenated to produce one library vcf each for the SNV and Indel pipelines. 
These library files were then filtered using a combination of vcftools v0.1.15 and bedtools v2.25 for 
read depth, quality score, and known PCR/sequence artefacts.13,14   Further filtering was 
accomplished using an in-house script to remove variants in intronic regions outside essential 
splicing sites, SNPs with a minor allele frequency <1% and synonymous changes.  The resulting 
novel variants were further scrutinised by reviewing the bam file to eliminate any potential 
PCR/sequence artefacts. 
The above in house variant calling pipeline was optimised and validated using two virtual sequence  
libraries containing a large number of various known somatic mutations: one contained lymphoma 
associated mutations (60 SNVs, 19 indels and 6 splicing variants), while the other included brain 
tumour associated mutations (5 SNVs, 11 indels), largely unrelated to the current study.   
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RESULTS   
1) Optimisation of experimental protocols 
In the initial study, a series of testing experiments were performed in duplicate to optimise the 
experimental protocols.   First, various amounts of template DNA (50 ng, 100 ng) from 
representative FFPE DLBCL tissue specimens (DNA samples amenable for PCR of up to 200bp (n=1), 
300bp (n=5) and 400bp (n=3) genomic fragment) with known mutations in 22 of the 70 genes 
investigated were used for HaloPlexHS target enrichment, followed by Illumina sequencing.   Based 
on the coverage and depth of sequencing, 100 ng DNA was considered as the minimal optimal 
amount of template DNA for the targeted sequencing (Figure S1A).  Second, we compared the 
sequence coverage among different Illumina sequencing platforms, namely MiSeq, HiSeq2500 and 
HiSeq4000 with compatible amounts of target enrichment library according to their sequencing 
capacity.   The results showed that HiSeq4000 yielded the highest overall sequence coverage and 
depth reads, much better than HiSe2500 based on analysis of 80 samples respectively (Figure S1B).  
Hence, Illumina HiSeq4000 was chosen for all of the subsequent experiments, with all of the data 
presented below being derived from optimised HaloPlexHS  target enrichment and Illumina 
HiSeq4000 sequence unless otherwise specified.       
2) Impact of DNA quality on sequence coverage and variant reproducibility   
A total of 266 FFPE DLBCL tissue specimens were investigated by targeted sequencing of 70 genes 
using HaloPlexHS  target enrichment and Illumina HiSeq4000.  As expected, the quality of DNA 
samples had a major impact on the target library quantity, overall sequence coverage as well as the 
read depth, with better quality of DNA samples clearly showing higher performance of these 
parameters (Figure 1A-D).  In addition, the DNA samples amplifiable for ≥400bp genomic fragments 
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showed a much lesser extent of variation in their sequence coverage than those only amplifiable for 
up to 300bp (Figure 1D).   There was also a correlation between the depth reads and the amplicon 
sizes, with higher depth reads in smaller rather than larger sized amplicons (Figure S2). 
To examine whether DNA quality had any impact on the reproducibility of variant detection, we 
next focused on the 93 cases where duplicate experiments starting from input DNA were carried 
out.  The variants identified by the in house variant calling pipeline were filtered to remove variants 
that were deemed unacceptable: <50 total read depth (TD), <5 alternative allele read depth (AAD), 
<2% alternative allele frequency (AAF), as well as known PCR/sequencing artefacts.  The resulting 
novel variants were interrogated between the two replicates, and recorded as reproducible or non-
reproducible changes, with the latter group being most likely false positives (Figure S3).  As shown 
in Figure 1E, the proportion of non-reproducible variants clearly depended on the quality of DNA, 
being much higher in DNA samples amplifiable for ≤300bp than those amplifiable for ≥400bp 
genomic fragment.  Importantly, a high proportion of these non-reproducible variants had a high 
AAF, limiting its value to separate reproducible from non-reproducible changes (Figure 1F).      
3) Determining cut-off parameters for reliable variant detection 
The HaloPlexHS  target enrichment design incorporates a molecular barcode, allowing removal of 
PCR duplicates, thus PCR errors.  In view of this, the number of reads that bear novel variants, i.e. 
alternative allele depth (AAD), would represent the copy number of “mutant” template that are 
successfully captured and sequenced.  Theoretically, this would be a good parameter to distinguish 
true genetic changes from false positives as the higher the AAD, the higher the probability of a 
variant originating from template DNA rather than experimental artefact.  As expected, all non-
reproducible variants in DNA samples amplifiable for ≥400bp or up to 300bp genomic fragment 
were at low AAD values with mean plus 2SD being <15 in both groups (Figure 2A&B).  To ensure 
10 
 
highly specific mutation detection, we used 20 AAD as the cut-off value for dichotomy between 
reproducible and non-reproducible variants.  This allowed detection of 97% reproducible variants 
with 100% specificity.   As all non-reproducible variants are below this cut-off value, theoretically a 
single replicate could be sufficient for reliable mutation detection if this threshold proved to be 
highly efficient and specific.  To verify this, we next examined the concordance in mutation 
detection between HaloPlexHS /Illumina HiSeq and Fluidigm/Illumina MiSeq approaches.   
Non-reproducible variants in DNA samples amplifiable for only up to 200bp genomic fragment were 
rather dispersed, with a high proportion showing relatively high AAD values (Figure 2C).     
4) Validation of mutation detection by HaloPlexHS /Illumina HiSeq sequencing   
Among the cases investigated by HaloPlexHS /Illumina HiSeq4000, 60 (22 in duplicate and 38 in a 
single replicate) were also investigated for mutations in 22 genes by Fluidigm Multiplex 
PCR/Illumina MiSeq in duplicate.  The novel variants that were considered as true genetic changes 
were identified independently by their respective protocols and thresholds,6 and then compared 
between the two different targeted sequencing approaches.  
Within the 22 cases that were investigated in duplicate by both Fluidigm and HaloPlexHS  
approaches, 60 and 61 novel variants were identified in the common region of 22 genes covered by 
these methods respectively, with 58 variants being mutually detected by both methods (Figure 3A).   
The 2 variants detected by Fluidigm but not HaloPlexHS  approach were found by the HaloPlexHS  
approach but not called as both variants were at the end of their amplicon, while the 3 variants 
detected by HaloPlexHS , but not Fluidigm approach were due to low AAF value.  
Of the 38 cases that were investigated in duplicate by the Fluidigm, but a single replicate by the 
HaloPlexHS approach, 96 and 98 novel variants were identified in the common region of 22 genes 
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covered by these methods respectively, with 91 variants being mutually detected by both methods 
(Figure 3B).   The 5 variants detected by Fluidigm but not the HaloPlexHS  approach were due to 
suboptimal AAD (6 and 12) in 2, low AAF in 2, and at the end of its amplicon in 1, while the 7 
variants detected by HaloPlexHS , but not the Fluidigm approach were due to low AAF value. 
Taken together, the above findings indicate that the target sequencing protocol by HaloPlexHS 
/Illumina HiSeq was highly sensitive and specific in mutation screening, comparable to the 
Fluidigm/Illumina MiSeq approach established previously.6  This was further supported by the 
similar mutation frequencies in DLBCL between the present and published studies.     
5) Nature of false positives from FFPE tissue DNA by HaloPlexHS  target enrichment 
For non-reproducible changes, C:G>T:A and C:G>A:T alterations accounted for the majority of single  
substitution changes, with other base changes including A:T>G:C (a feature of PCR errors) being at 
relatively low frequencies (Figure S4).  In contrast, a wide spectrum of substitution changes was 
seen for the reproducible changes above the 20 AAD cut-off value.   There was no apparent 
correlation between the type of substitution changes and the quality of DNA samples.  
 
DISCUSSION  
In this study, we have developed a targeted sequencing protocol for mutation screening using 
HaloPlexHS  target enrichment, the Illumina HiSeq platform and an in house variant calling 
algorithm that was validated against virtual sequence libraries containing a large number of known 
mutations.   By performing the targeted sequencing in duplicate and validating the detected 
variants against an independent targeted sequencing protocol, namely Fluidigm Access Array PCR 
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and Illumina MiSeq sequencing,6 we have established a stratified approach for mutation screening 
using DNA samples from FFPE tissues (Figure 4).     
Stratified targeted sequencing approach according to DNA quality   
Under the defined experimental and data analysis protocol and the proposed 20 AAD cut-off value, 
reliable mutation screening could be achieved by a single replicate for DNA samples amenable for 
good amplification of ≥400bp genomic fragments.  This is evident by the excellent overall sequence 
coverage, read depth and highly sensitive and specific detection of known mutations in these 
samples.  
For DNA samples showing good amplification of up to 300bp genomic fragments, reliable mutation 
detection could still be obtained by a single replicate in the sequence regions that were adequately 
captured and sequenced.  This is evident by the absence of any non-reproducible variants above 
the 20 AAD cut-off value.  However, the overall sequence coverage in these samples is relatively 
low, with an average of ~8% (ranging 4-16%) targeted sequences not adequately captured and 
sequenced when only a single replicate was carried out (Figure 1D).  In addition, the extent of non-
reproducible variants is much higher than those amenable for PCR of >400bp (Figure 1E).  In view of 
these concerns, these samples are best sequenced in duplicate, which not only improves the 
sequence coverage albeit moderately, but also enables mutation detection based on reproducible 
variants, further ensuring the detection specificity (Figure S5).          
For DNA samples that are amplifiable for only up to 200bp genomic fragments, reliable mutation 
screening could not be achieved due to poor sequence coverage and substantial numbers of non-
reproducible variants above the proposed AAD cut-off value (Figure 1B-D, Figure 2C).  Such samples 
are best excluded from targeted sequencing using the above experimental conditions.   Although it 
remains to be investigated whether an increase of library quantity from DNA samples of poor 
quality would improve the sequence coverage,  the vast majority of sequence reads in such samples 
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were from re-amplified products (Figure S2), indicating suboptimal enrichment of the targeted 
sequences.   A more efficient approach to work on DNA samples of poor quality is to redesign the 
probes by targeting and amplifying smaller sized sequence fragments.           
It is important to note that the above AAD cut-off value for dichotomy between reproducible and 
non-reproducible variants and the proposed stratified targeted sequencing approach according to 
DNA quality were based on the experimental and data analysis protocols defined in this study.  The 
AAD cut-off value most likely varies depending on the experimental protocol and data analysis 
pipeline, and thus should be experimentally determined for the methodology to be employed.        
Although the cost for next generation sequencing is decreasing, targeted sequencing is still costly 
due to the expensive target enrichment kit and relatively high cost for running fast sequencing 
platforms such as Illumina MiSeq and HiSeq2500.  The above stratified approach would improve the 
cost effectiveness.  Based on our ongoing works, 92% of DNA samples from FFPE DLBCL tissue 
biopsies recruited to an ongoing MaPLe clinical trial would be adequate for targeted sequencing 
using a single replicate.   Nonetheless, the proportion of such good DNA samples was relatively 
lower in the earlier REMoDL-B trial (tissue specimens stored for an average 4 years, range 2-6 years) 
(87%) and archival population based DLBCL (tissue specimens stored for an average 9 years, range 5 
-13 years) (44%), most likely reflecting variation and deterioration of DNA quality during tissue 
storage.   
 
Detection of low burden mutations   
As shown in Figure 2A&B, there was a considerable overlap among the reproducible and non-
reproducible variants below the 20 AAD cut-off value, with those below 15 AAD being largely non-
reproducible changes.  For the variants between 15-20 AAD, it is not possible to ascertain their 
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nature, i.e. true genetic change or false positive if targeted sequencing was performed in a single 
replicate.  Nonetheless, these variants were small in number, and so could be validated by an 
independent approach such as Sanger sequencing (Figure 4).   A high proportion of these variants 
could be subclonal genetic changes, and may be beyond the sensitivity of Sanger sequencing 
detection.  Practically,  these variants could be amplified by conventional PCR, selectively pooled 
and barcoded, then sequenced with an Illumina MiSeq platform.     
To maximise the sensitivity and specificity of mutation detection, it is critical to use specimens with 
high tumour cell content for DNA extraction, and where necessary to enrich tumour cell population 
by microdissection, as this will improve the separation of true genetic changes from background 
noise.  We compared the extent of reproducible variants below 20 AAD according to tumour load, 
and found that this accounted for only 2% of the total reproducible variants in DNA samples with 90% 
tumour cell content, but 5% of the total reproducible variants in those with 20-50% tumour cell 
content.             
Nature of non-reproducible variants 
In the previous study by Fluidigm Access Array PCR and Illumina MiSeq, the vast majority of non-
reproducible variants in DNA samples from FFPE tissues were PCR errors (A:T>G:C changes) and 
changes resulting from cytosine deamination (C:G>T:A).6  In contrast to the Fluidigm approach, the 
present HaloPlexHS protocol showed a low level of A:T>G:C changes among non-reproducible 
variants, indicating that the incorporation of a molecular barcode in the HaloPlexHS  target 
enrichment design was highly efficient in removing PCR errors.  Importantly, this has made it 
possible for reliable mutation screening by targeted sequencing with a single replicate when the 
quality of DNA sample is adequate. 
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In summary, we have established a protocol with defined cut-off values for highly sensitive and 
specific mutation screening by HaloPlexHS  target enrichment and Illumina sequencing, and 
provided a practical and stratified approach for mutation analysis using DNA samples from FFPE 
tissues according to their quality.  We are currently using this established protocol to perform 
mutation profiling in DLBCL recruited to the REMoDL-B and MaPLe trials.       
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FIGURE LEGENDS 
Figure 1. Impact of DNA quality on sequence coverage and variant detection reproducibility.  
A) Assessment of DNA quality by PCR of variably sized genomic fragments under a standardised 
protocol.6  The class of DNA quality is indicated at the top of each lane.  
B)  Average reads before and after removal PCR duplicate according to DNA quality.  For DNA 
samples amenable for PCR of >400bp, an average of at least 1300 reads after deduplication is 
achieved.    
C) Overall sequence coverage according to DNA quality.   Sequence coverage is calculated based on 
per nucleotide and the percentage of the targeted sequences that are covered by more than 50 
reads is given.  DNA samples that support PCR of variable genomic fragment are indicated 
accordingly.   
D) Correlation among DNA quality, target library quantity and overall sequence coverage (>50 
reads).  In general, DNA samples that support PCR of >400bp genomic fragment yield much higher 
quantity of target sequence libraries and excellent sequencing coverage, while those that support 
PCR of only up to 300bp genomic fragment generate much lower quantity of target sequence 
libraries and suboptimal sequencing coverage.  Mean and SD of sequencing coverage are provided 
according to DNA quality.   
E) Extent of non-reproducible variants according to DNA quality.  The analysis is based on variants 
after initial filtering to remove those deemed unacceptable:   <50 total read depth, <5 alternative 
allele read depth, <2% alternative allele frequency, as well as known PCR/sequencing artefacts. 
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F) Comparison of alternative allele frequency (AAF) between reproducible and non-reproducible 
variants according to DNA quality.   There is considerable overlap in AAF between reproducible and 
non-reproducible variants regardless of their DNA quality, hence limiting its value in identification 
of true genetic changes.      
Figure 2.   Alternative allele depth (AAD) as an effective parameter in dichotomy between 
reproducible and non-reproducible variants.   In general, the AAD value for non-reproducible 
variants is low, particularly in DNA samples that support PCR of 300bp or more genomic fragments, 
with mean plus 2SD being less than 15 AAD.  To ensure highly specific mutation detection, a cut-off 
value of 20 AAD is used for dichotomy between reproducible and non-reproducible variants.   
Figure 3. : Concordance in mutation detection between the HaloPlexHS and Fluidigm target 
enrichment approach under their respective protocols. 
Figure 4.  Proposed stratified approach for mutation screening by HaloplexHS target enrichment 
and Illumina HiSeq4000 sequencing according to DNA quality.  The DNA samples that support PCR 
of ≥400bp genomic fragment are amenable for mutation analysis with a single replicate, with only 
variants at 15-20 AAD required for further validation, while those with suboptimal quality (PCR of 
up to 300bp) are better analysed in duplicate with reproducible variants >15 AAD regarded as true 
genetic changes. DNA samples that support PCR of only 200bp genomic fragment are not suitable 
for targeted sequencing under the conditions specified.     
 




